ERBB2 and breast carcinoma: They previously found that in HER2-positive tumors, some bromodomain transcripts contributed to detrimental prognosis [135], as bromo and extra terminal domains (BET) family of proteins have played a role in promoting different tumors and the BET inhibitor (BETi) have been described as potential drugs to treat breast cancer [136].